These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 9734107)

  • 1. [Cost evaluation of therapeutic management of patients with chronic hepatitis C].
    Faure C; Gasser P; Douet MC
    Therapie; 1997; 52(6):553-8. PubMed ID: 9734107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
    Lidgren M; Hollander A; Weiland O; Jönsson B
    Scand J Gastroenterol; 2007 Jul; 42(7):867-77. PubMed ID: 17558912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Medico-economic assessment of the therapeutic management of patients with hepatitis C].
    Loubière S; Rotily M; Moatti JP
    Gastroenterol Clin Biol; 2000 Nov; 24(11):1047-51. PubMed ID: 11139674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of interferon alpha plus ribavirin on health-related quality of life in chronic C hepatitis. The Romanian experience.
    Pojoga C; Dumitraşcu DL; Pascu O; Grigorescu M
    J Gastrointestin Liver Dis; 2006 Mar; 15(1):31-5. PubMed ID: 16680230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronic hepatitis C drug therapy update].
    Ruano Camps R; Gallego Fernández C
    Farm Hosp; 2003; 27(6):371-85. PubMed ID: 14974883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Quality of care and health economics in occupationally acquired hepatitis C in German health care workers between 1993 and 2004].
    Reiser M; Haverkamp A; Dintsios M; Mölleken C; Krauth C; Pieper W; Schmiegel W
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1743-7. PubMed ID: 17713882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A.
    Jacobs RJ; Koff RS; Meyerhoff AS
    Am J Gastroenterol; 2002 Feb; 97(2):427-34. PubMed ID: 11866283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States.
    Arguedas MR; Heudebert GR; Fallon MB; Stinnett AA
    Am J Gastroenterol; 2002 Mar; 97(3):721-8. PubMed ID: 11922569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.
    Bargiggia S; Thorburn D; Anderloni A; Ardizzone S; Giorgi A; Bianchi Porro G; Parente F
    Aliment Pharmacol Ther; 2005 Aug; 22(3):209-15. PubMed ID: 16091058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.
    Aggarwal R; Ghoshal UC; Naik SR
    Natl Med J India; 2002; 15(6):320-7. PubMed ID: 12540064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV.
    Sterling RK; Brown RS; Hofmann CM; Luketic VA; Stravitz RT; Sanyal AJ; Contos MJ; Mills AS; Smith V; Shiffman ML
    Am J Gastroenterol; 2005 Feb; 100(2):313-21. PubMed ID: 15667488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis applied to the treatment of burn patients in a specialized center.
    Sánchez JL; Perepérez SB; Bastida JL; Martínez MM
    Arch Surg; 2007 Jan; 142(1):50-7; discussion 57. PubMed ID: 17224500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic decision analysis to determine optimal treatment duration in chronic hepatitis C.
    Veldt BJ; Hansen BE; Eijkemans MJ; de Knegt RJ; Stijnen T; Habbema JD; Schalm SW
    Aliment Pharmacol Ther; 2005 Mar; 21(5):539-47. PubMed ID: 15740537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the treatment of hepatitis C.
    Lawrence SP
    Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The retreatment with natural leukocyte interferon alfa-n3 of chronic hepatitis C patients: the intolerant and nonresponsive results to prior treatment with recombinant alfa interferon].
    Cagnoni C; Pancotti D; Carrara G
    Ann Ital Med Int; 1999; 14(3):159-65. PubMed ID: 10566181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct economic burden of chronic hepatitis C virus in a United States managed care population.
    Davis KL; Mitra D; Medjedovic J; Beam C; Rustgi V
    J Clin Gastroenterol; 2011 Feb; 45(2):e17-24. PubMed ID: 20628308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How did chronic hepatitis C impact costs related to hospital health care in France in 2009?
    Rotily M; Vainchtock A; Jouaneton B; Wartelle-Bladou C; Abergel A
    Clin Res Hepatol Gastroenterol; 2013 Sep; 37(4):365-72. PubMed ID: 23273498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential need for research in hepatitis C.
    McCombs JS
    J Med Econ; 2015; 18(7):512-3. PubMed ID: 25687753
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply: Essential need for research in hepatitis C.
    Tandon N; Balart LA; Laliberté F; Pilon D; Lefebvre P; Germain G; Prabhakar A
    J Med Econ; 2015; 18(7):514-5. PubMed ID: 25744591
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.